Unique technology, unique market
Xspray’s technology enables the creation of improved drugs, bettering or even saving patients’ lives. The unique technology also opens the opportunity to enter a multi billion market for cancer medicine, where competition is low.
Latest report
Interim Report Q3 2020Subscribe
Get our latest press releases and reports

Press releases
Regulatory press release 2021-01-14
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)
Press release 2020-12-30
Xspray Pharma reports positive results from a study with dasatinib during omeprazole treatment
Regulatory press release 2020-12-29
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
Press release 2020-12-17
Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
Regulatory press release 2020-12-11
Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application

Xspray’s patented method to create amorphous forms of drugs, makes it possible to enter the market long before the generic companies, with a cheaper version of the original drug. The amorphous form of Xspray’s drug renders the original company’s secondary patent, which protects certain crystalline patterns, ineffective. This creates a window over several years, where Xspray becomes sole competitor on a multi billion dollar market.

We see a large potential for development the next few years. Out technology works for most of the 54 U.S. approved protein kinase inhibitors. The process of development and commercialisation we are establishing right now, on our first product HyNap-Dasa, will be applicable for all coming product candidates. We see a growing interest from our potential partners. This is an exciting time! Per Andersson, CEO